Shareholder rights law firm Robbins LLP is investigating Co-Diagnostics, Inc. (NASDAQ: CODX) and its officers and directors to determine whether they breached fiduciary duties and violated securities laws by misleading investors regarding demand for the Company's Logix Smart™ COVID-19 Test. Co-Dx purports to develop, manufacture, and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), including robust and innovative molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural application.

If you would like more information about our investigation of Co-Diagnostics, Inc.'s misconduct, click here.

What is this Case About: According to the complaint filed against Co-Dx, on April 6, 2020, Co-Dx announced it had received Emergency Use Authorization for its Logix Smart™ COVID-19 detection test from the FDA, allowing it to commence sales of the test to laboratories certified by the Center for Medicare and Medicaid Services under the Clinical Laboratories Improvements Act (“CLIA”) to accept human samples for diagnostics testing throughout the United States. Co-Dx has sold its Logix Smart™ COVID-19 test to such CLIA labs since that time.

During the class period, defendants touted the Logix Smart COVID-19 Test, reassuring investors about the demand for the product. At the same time, defendants failed to disclose that: (1) demand for its Logix Smart™ COVID-19 Test had plummeted throughout the quarter ended June 30, 2022, and (2) as a result, Defendants’ positive statements about the demand for its Logix Smart™ COVID-19 Test lacked a reasonable basis.

On August 11, 2022, Co-Dx announced its financial results for the quarter ended June 30, 2022, in which the Company disclosed revenue of $5.0 million for the quarter ended June 30, 2022, down from $27.4 million during the prior year period, a decline of almost 82%. The Company primarily attributed the decrease to lower demand of the Logix Smart™ COVID-19 Test. On this news, the price of Co-Dx's stock fell almost $2.00, or 30.65%, to close at $4.48 per share on August 12, 2022.

Next Steps: If you acquired shares of Co-Diagnostics, Inc. between May 12, 2022 and August 11, 2022, you have legal options. Contact Robbins LLP for information about your rights and remedies.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Contact us to learn more:

Aaron Dumas

(800) 350-6003

adumas@robbinsllp.com

Shareholder Information Form

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Co-Diagnostics, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220824005676/en/